// App-Quantinova.ai

987 : A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases

Researchers

Presenter

  • Stacey Dillon

Principal Investigators

  • Pille Harrison

  • Jason Lickliter

  • Kristi Manjarrez

  • Alina Smith

  • Mary Lessig

  • Lori Blanchfield

  • Russell Sanderson

  • Allison Chunyk

  • Tiffany Blair

  • Amanda Enstrom

  • Martin Wolfson

  • Mark Rixon

  • Hany Zayed

  • Rupert Davies

  • Stanford Peng

Medical Centers

  • Alpine Immune Sciences, Seattle, WA.

  • Alpine Immune Sciences, Taunton, United Kingdom

  • Nucleus Network, Melbourne, Australia

  • Alpine Immune Sciences, San Francisco, CA

Locations

  • United States

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • B-cell activating factor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Pharmacodynamics

  • Single Ascending Dose

  • Controlled

  • Cohort

  • First-In-Human

Phase

  • I

Study Id's

  • NCT05034484

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved